目的 探討胃炎康膠囊聯(lián)合鋁碳酸鎂治療膽汁反流性胃炎的臨床療效。方法 選取2011年3月-2015年3月在子洲縣中醫(yī)院接受治療的膽汁反流性胃炎患者100例，隨機(jī)分為對(duì)照組（50例）和治療組（50例）。對(duì)照組患者口服鋁碳酸鎂片，2片/次，3次/d。治療組在對(duì)照組的基礎(chǔ)上口服胃炎康膠囊，8粒/次，3次/d。兩組患者均連續(xù)治療4周。觀察兩組的臨床療效，同時(shí)比較兩組患者治療前后的胃黏膜充血、水腫和糜爛評(píng)分、臨床癥狀總積分、生活質(zhì)量總積分、胃液膽酸水平、胃酸分泌量以及血清血管活性腸肽（VIP）和白細(xì)胞介素-6（IL-6）水平。結(jié)果 治療后，對(duì)照組和治療組的總有效率分別為86.00%、98.00%，兩組總有效率比較差異有統(tǒng)計(jì)學(xué)意義（P<0.05）。治療后，兩組患者胃黏膜充血、水腫和糜爛評(píng)分顯著降低，同組治療前后差異具有統(tǒng)計(jì)學(xué)意義（P<0.05）；且治療組這些觀察指標(biāo)的降低程度優(yōu)于對(duì)照組，兩組比較差異具有統(tǒng)計(jì)學(xué)意義（P<0.05）。治療后，兩組臨床癥狀和生活質(zhì)量總積分均顯著降低，同組治療前后差異具有統(tǒng)計(jì)學(xué)意義（P<0.05）；且治療組這些觀察指標(biāo)明顯低于對(duì)照組，兩組比較差異具有統(tǒng)計(jì)學(xué)意義（P<0.05）。治療后，兩組患者液膽酸水平、胃酸分泌量均顯著降低，同組治療前后差異具有統(tǒng)計(jì)學(xué)意義（P<0.05）；且治療組這些觀察指標(biāo)明顯低于對(duì)照組，兩組比較差異具有統(tǒng)計(jì)學(xué)意義（P<0.05）。治療后，兩組患者血清VIP和IL-6水平均明顯降低，同組比較差異具有統(tǒng)計(jì)學(xué)意義（P<0.05）；與對(duì)照組相比，治療組降低的更明顯，兩組比較差異具有統(tǒng)計(jì)學(xué)意義（P<0.05）。結(jié)論 胃炎康膠囊聯(lián)合鋁碳酸鎂治療膽汁反流性胃炎療效顯著，可顯著改善患者臨床癥狀，保護(hù)胃黏膜，提高患者生活質(zhì)量，具有一定的臨床推廣應(yīng)用價(jià)值。

Objective To investigate the clinical effect of Weiyankang Capsules combined with hydrotalcite in treatment of bile reflux gastritis. Methods Patients (100 cases) with bile reflux gastritis in Zizhou County Hospital of TCM from March 2011 to March 2015 were enrolled in this study and divided into control (50 cases) and treatment (50 cases) groups. The patients in the control group were po administered with Hydrotalcite Tablets, 2 tablets/time, three times daily. The patients in the treatment group were po administered with Weiyankang Capsules on the basis of control group, 8 grains/time, three times daily. The patients in two groups were treated for 4 weeks. After treatment, clinical efficacy was evaluated, and scores of congestion, edema and erosion of gastric mucosa, and clinical symptoms total scores, life quality total scores, bile acid content in gastric juice, gastric acid secretion capacity, and serum levels of VIP and IL-6 in two groups before and after treatment were compared. Results After treatment, the efficacies of the control and treatment groups were 86.00% and 98.00%, respectively, and there was significant difference between groups (P<0.05). After treatment, the scores of congestion, edema and erosion of gastric mucosa in two groups were significantly decreased, and the difference was statistically significant in the same group (P<0.05). And the observational indexes in the treatment group were significantly lower than those in the control group, with significant difference between two groups (P<0.05). After treatment, the total scores of clinical symptoms and life quality in two groups were significantly decreased, and the difference was statistically significant in the same group (P<0.05). And the observational indexes in the treatment group were significantly lower than those in the control group, with significant difference between two groups (P<0.05). After treatment, bile acid content in gastric juice and gastric acid secretion capacity in two groups were significantly decreased, and the difference was statistically significant in the same group (P<0.05). And the observational indexes in the treatment group were significantly lower than those in the control group, with significant difference between two groups (P<0.05). After treatment, serum levels of VIP and IL-6 in two groups were significantly decreased, and the difference was statistically significant in the same group (P<0.05). And compared with the control group, the observational indexes in the treatment group were decreased more significantly, with significant difference between two groups (P<0.05). Conclusion Weiyankang Capsules combined with hydrotalcite has a significant curative effect in treatment of bile reflux gastritis, can protect the gastric mucosa and significantly improve the clinical symptoms and quality of life, which has a certain clinical application value.